Phase 2, double-blind, placebo-controlled, dose-response trial of intravenous adenosine for perioperative analgesia

Ashraf S. Habib, Harold Minkowitz, Timothy Osborn, Babatunde Ogunnaike, Keith A Candiotti, Eugene Viscusi, Jiezhun Gu, Mary R. Creed, Tong J. Gan

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

BACKGROUND:: Adenosine regulates pain transmission by actions at spinal, supraspinal, and peripheral sites. A few studies have suggested that administration of adenosine might be associated with anesthetic- and analgesic-sparing effects. The primary aim of this multicenter study was to determine the dose-response profile of adenosine with respect to perioperative analgesia. METHODS:: Women undergoing major gynecologic surgery were enrolled. Subjects were randomly assigned to receive one of four doses of adenosine (25, 50, 100, or 200 μg • kg • min) or matching placebo. A dose-escalation cohort approach was followed. Study drug administration was started in the operating room at the time of skin incision and discontinued at the end of surgery. The anesthetic technique was standardized. Postoperative analgesia was provided with a standardized morphine patient-controlled analgesia system. Data were collected in the hospital and after discharge daily through postoperative day 7. RESULTS:: A total of 166 subjects received treatment with study drug: 125 received adenosine and 41 received placebo. Except for height, there were no differences between treatment groups with respect to demographic or baseline characteristics. Cumulative opioid use during the initial 24-h period after extubation was not significantly different between treatment groups. There were also no differences between treatment groups with respect to cumulative anesthetic use, intraoperative opioid requirements, pain scores, sedation, time to readiness for discharge from the postanesthesia care unit, time to readiness for discharge from the hospital, opioid-related symptom distress scores, patient satisfaction with pain control, and occurrence of adverse events. CONCLUSIONS:: There were no differences between placebo and adenosine with respect to efficacy and safety for perioperative analgesia.

Original languageEnglish
Pages (from-to)1085-1091
Number of pages7
JournalAnesthesiology
Volume109
Issue number6
DOIs
StatePublished - Dec 1 2008

Fingerprint

Adenosine
Analgesia
Placebos
Opioid Analgesics
Anesthetics
Pain
Patient-Controlled Analgesia
Gynecologic Surgical Procedures
Operating Rooms
Therapeutics
Patient Satisfaction
Pharmaceutical Preparations
Morphine
Multicenter Studies
Analgesics
Demography
Safety
Skin

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Phase 2, double-blind, placebo-controlled, dose-response trial of intravenous adenosine for perioperative analgesia. / Habib, Ashraf S.; Minkowitz, Harold; Osborn, Timothy; Ogunnaike, Babatunde; Candiotti, Keith A; Viscusi, Eugene; Gu, Jiezhun; Creed, Mary R.; Gan, Tong J.

In: Anesthesiology, Vol. 109, No. 6, 01.12.2008, p. 1085-1091.

Research output: Contribution to journalArticle

Habib, AS, Minkowitz, H, Osborn, T, Ogunnaike, B, Candiotti, KA, Viscusi, E, Gu, J, Creed, MR & Gan, TJ 2008, 'Phase 2, double-blind, placebo-controlled, dose-response trial of intravenous adenosine for perioperative analgesia', Anesthesiology, vol. 109, no. 6, pp. 1085-1091. https://doi.org/10.1097/ALN.0b013e31818db88c
Habib, Ashraf S. ; Minkowitz, Harold ; Osborn, Timothy ; Ogunnaike, Babatunde ; Candiotti, Keith A ; Viscusi, Eugene ; Gu, Jiezhun ; Creed, Mary R. ; Gan, Tong J. / Phase 2, double-blind, placebo-controlled, dose-response trial of intravenous adenosine for perioperative analgesia. In: Anesthesiology. 2008 ; Vol. 109, No. 6. pp. 1085-1091.
@article{322b55c0beec467f902519ff3397fded,
title = "Phase 2, double-blind, placebo-controlled, dose-response trial of intravenous adenosine for perioperative analgesia",
abstract = "BACKGROUND:: Adenosine regulates pain transmission by actions at spinal, supraspinal, and peripheral sites. A few studies have suggested that administration of adenosine might be associated with anesthetic- and analgesic-sparing effects. The primary aim of this multicenter study was to determine the dose-response profile of adenosine with respect to perioperative analgesia. METHODS:: Women undergoing major gynecologic surgery were enrolled. Subjects were randomly assigned to receive one of four doses of adenosine (25, 50, 100, or 200 μg • kg • min) or matching placebo. A dose-escalation cohort approach was followed. Study drug administration was started in the operating room at the time of skin incision and discontinued at the end of surgery. The anesthetic technique was standardized. Postoperative analgesia was provided with a standardized morphine patient-controlled analgesia system. Data were collected in the hospital and after discharge daily through postoperative day 7. RESULTS:: A total of 166 subjects received treatment with study drug: 125 received adenosine and 41 received placebo. Except for height, there were no differences between treatment groups with respect to demographic or baseline characteristics. Cumulative opioid use during the initial 24-h period after extubation was not significantly different between treatment groups. There were also no differences between treatment groups with respect to cumulative anesthetic use, intraoperative opioid requirements, pain scores, sedation, time to readiness for discharge from the postanesthesia care unit, time to readiness for discharge from the hospital, opioid-related symptom distress scores, patient satisfaction with pain control, and occurrence of adverse events. CONCLUSIONS:: There were no differences between placebo and adenosine with respect to efficacy and safety for perioperative analgesia.",
author = "Habib, {Ashraf S.} and Harold Minkowitz and Timothy Osborn and Babatunde Ogunnaike and Candiotti, {Keith A} and Eugene Viscusi and Jiezhun Gu and Creed, {Mary R.} and Gan, {Tong J.}",
year = "2008",
month = "12",
day = "1",
doi = "10.1097/ALN.0b013e31818db88c",
language = "English",
volume = "109",
pages = "1085--1091",
journal = "Anesthesiology",
issn = "0003-3022",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Phase 2, double-blind, placebo-controlled, dose-response trial of intravenous adenosine for perioperative analgesia

AU - Habib, Ashraf S.

AU - Minkowitz, Harold

AU - Osborn, Timothy

AU - Ogunnaike, Babatunde

AU - Candiotti, Keith A

AU - Viscusi, Eugene

AU - Gu, Jiezhun

AU - Creed, Mary R.

AU - Gan, Tong J.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - BACKGROUND:: Adenosine regulates pain transmission by actions at spinal, supraspinal, and peripheral sites. A few studies have suggested that administration of adenosine might be associated with anesthetic- and analgesic-sparing effects. The primary aim of this multicenter study was to determine the dose-response profile of adenosine with respect to perioperative analgesia. METHODS:: Women undergoing major gynecologic surgery were enrolled. Subjects were randomly assigned to receive one of four doses of adenosine (25, 50, 100, or 200 μg • kg • min) or matching placebo. A dose-escalation cohort approach was followed. Study drug administration was started in the operating room at the time of skin incision and discontinued at the end of surgery. The anesthetic technique was standardized. Postoperative analgesia was provided with a standardized morphine patient-controlled analgesia system. Data were collected in the hospital and after discharge daily through postoperative day 7. RESULTS:: A total of 166 subjects received treatment with study drug: 125 received adenosine and 41 received placebo. Except for height, there were no differences between treatment groups with respect to demographic or baseline characteristics. Cumulative opioid use during the initial 24-h period after extubation was not significantly different between treatment groups. There were also no differences between treatment groups with respect to cumulative anesthetic use, intraoperative opioid requirements, pain scores, sedation, time to readiness for discharge from the postanesthesia care unit, time to readiness for discharge from the hospital, opioid-related symptom distress scores, patient satisfaction with pain control, and occurrence of adverse events. CONCLUSIONS:: There were no differences between placebo and adenosine with respect to efficacy and safety for perioperative analgesia.

AB - BACKGROUND:: Adenosine regulates pain transmission by actions at spinal, supraspinal, and peripheral sites. A few studies have suggested that administration of adenosine might be associated with anesthetic- and analgesic-sparing effects. The primary aim of this multicenter study was to determine the dose-response profile of adenosine with respect to perioperative analgesia. METHODS:: Women undergoing major gynecologic surgery were enrolled. Subjects were randomly assigned to receive one of four doses of adenosine (25, 50, 100, or 200 μg • kg • min) or matching placebo. A dose-escalation cohort approach was followed. Study drug administration was started in the operating room at the time of skin incision and discontinued at the end of surgery. The anesthetic technique was standardized. Postoperative analgesia was provided with a standardized morphine patient-controlled analgesia system. Data were collected in the hospital and after discharge daily through postoperative day 7. RESULTS:: A total of 166 subjects received treatment with study drug: 125 received adenosine and 41 received placebo. Except for height, there were no differences between treatment groups with respect to demographic or baseline characteristics. Cumulative opioid use during the initial 24-h period after extubation was not significantly different between treatment groups. There were also no differences between treatment groups with respect to cumulative anesthetic use, intraoperative opioid requirements, pain scores, sedation, time to readiness for discharge from the postanesthesia care unit, time to readiness for discharge from the hospital, opioid-related symptom distress scores, patient satisfaction with pain control, and occurrence of adverse events. CONCLUSIONS:: There were no differences between placebo and adenosine with respect to efficacy and safety for perioperative analgesia.

UR - http://www.scopus.com/inward/record.url?scp=58149288597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149288597&partnerID=8YFLogxK

U2 - 10.1097/ALN.0b013e31818db88c

DO - 10.1097/ALN.0b013e31818db88c

M3 - Article

C2 - 19034105

AN - SCOPUS:58149288597

VL - 109

SP - 1085

EP - 1091

JO - Anesthesiology

JF - Anesthesiology

SN - 0003-3022

IS - 6

ER -